“When we learned a clinical trial [completed 2021] was an option after Leighton's allergic reaction [to E. coli-derived asparaginase therapy], I was so happy. That meant there was another avenue to make sure Leighton could get the asparaginase therapy her little body needed.”
- Leighton’s Father (Actual Patient Family)
What makes RYLAZE different
After an allergic reaction to asparaginase derived from E. coli
Continue the treatment journey with RYLAZE
RYLAZE is the only Erwinia asparaginase approved by the Food and Drug Administration to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in patients who have had an allergic reaction to asparaginase derived from E. coli.
RYLAZE is a prescription medicine that is part of a multi-agent chemotherapy regimen used to treat adults and children 1 month or older who have ALL or LBL after an allergic reaction to E. coli asparaginase.
RYLAZE: When a different type of asparaginase is needed
Allergic reactions are a sign that an asparaginase therapy isn't working as it should.
After an allergic reaction to asparaginase derived from E. coli, the doctor may switch to RYLAZE so treatment can continue as intended.
RYLAZE works in the body like other asparaginase therapies, but it is derived from Erwinia chrysanthemi instead of E. coli.
- Like other asparaginase therapies, RYLAZE may cause allergic reactions. Seek medical advice immediately if symptoms of an allergic reaction occur.